BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30219280)

  • 1. Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.
    Sunakawa Y; Yang D; Cao S; Zhang W; Moran M; Astrow SH; Hsiang J; Stephens C; Tsuji A; Takahashi T; Tanioka H; Negoro Y; Takagane A; Tani S; Yamaguchi T; Eto T; Fujii M; Ichikawa W; Lenz HJ
    Clin Colorectal Cancer; 2018 Dec; 17(4):e741-e749. PubMed ID: 30219280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
    Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
    Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
    Dirican A; Varol U; Kucukzeybek Y; Alacacioglu A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Yildiz Y; Koyuncu B; Coban E; Tarhan MO
    Asian Pac J Cancer Prev; 2014; 15(12):4781-6. PubMed ID: 24998541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer.
    Zhou Y; Zhang J; Dan Pu ; Bi F; Chen Y; Liu J; Li Q; Gou H; Wu B; Qiu M
    Anticancer Drugs; 2019 Feb; 30(2):195-200. PubMed ID: 30570508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
    Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab.
    Li Z; Chen Y; Ren WU; Hu S; Tan Z; Wang Y; Chen Y; Zhang J; Wu J; Li T; Xu J; Ying X
    Cancer Genomics Proteomics; 2019; 16(3):207-219. PubMed ID: 31018951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
    Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
    Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
    Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
    Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of survival after radioembolization for metastatic colorectal cancer.
    Tohme S; Sukato D; Chalhoub D; McDonald KA; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    Ann Surg Oncol; 2015 May; 22(5):1701-7. PubMed ID: 25190128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
    Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.
    Larsen FO; Jensen BV; Nørgaard HH; Hermann HK; Larsen PN; Markussen A; Hogdall E; Nielsen D
    Oncology; 2019; 96(6):299-308. PubMed ID: 30999314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
    Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
    Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer.
    Cruz-Ramos M; Del Puerto-Nevado L; Zheng B; López-Bajo R; Cebrian A; Rodríguez-Remirez M; García-García L; Solanes-Casado S; García-Foncillas J
    J Geriatr Oncol; 2019 Sep; 10(5):742-748. PubMed ID: 30327283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.